This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
The LRRK2 Cohort Consortium (LCC) comprises three closed studies: the LRRK2 Cross-sectional Study, LRRK2 Longitudinal Study and the 23andMe Blood Collection Study. The LCC followed standardized data acquisition protocols, and clinical data and biological samples are stored in a comprehensive Parkinson’s database and biorepository, respectively. A total of 1,213 Idiopathic PD subjects, 1,168 PD subjects with genetic mutations in LRRK2, 1,123 unaffected subjects with genetic mutations in LRRK2, and 779 Healthy Controls (HC) were recruited.
Types Neurodegenerative disease-specific cohort
Participant Types At-risk diagnosis|Condition diagnosed|No diagnosis
Countries Canada|China|France|Germany|Israel|Norway|Spain|Tunisia|USA
Genders Male and Female
Sample sizes 0 to 4,999
Ages
Brain related measures
Funtional rating Individual physiological|Individual psychological
Anthropometric Blood pressure
Physical Cardiovascular|Musculoskeletal|Reproductive|Respiratory
Biological samples Blood|Cerebral spinal fluid (CSF)|Other|Urine
Genotyping Gene screening
Brain imaging Magnetic resonance imaging (MRI)|Positron emission tomography (PET) fluorine18 flurodeoxyglucose (FDG)|Single photon emission computerised tomography (SPECT)
Brain banking
Lifestyle Alcohol|Dietary habits|Physical activity|Smoking
Socio-economic Education|Ethnic group|Family circumstances
Health service utilisation
Institute names The Michael J. Fox Foundation for Parkinson’s Research
Current Sample Sizes 0 to 4,999
age at recruitment
last updated
recruitment period 2011-2015
estimated current sample size number value
cohort acronym LCC
start date 2011-2015
pi
website https://www.michaeljfox.org/page.html?lrrk2-cohort-consortium&navid=lrrk2-cohort-consortium
contact details
abstract The LRRK2 Cohort Consortium (LCC) comprises three closed studies: the LRRK2 Cross-sectional Study, LRRK2 Longitudinal Study and the 23andMe Blood Collection Study. 1,213 Idiopathic PD subjects, 1,168 PD subjects with genetic mutations in LRRK2, 1,123 unaffected subjects with genetic mutations in LRRK2, and 779 Healthy Controls (HC) were recruited.
funders The Michael J. Fox Foundation for Parkinsons Research
contact email [email protected]
contact phone number 212-509-0995
estimated current sample size
sample sizes